コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 epiness) to 24 points (high level of daytime sleepiness).
2 0-24, with values <10 suggesting no daytime sleepiness).
3 ] >or= 5/hour, and >or= 2 symptoms including sleepiness).
4 study for patients with unexplained daytime sleepiness.
5 y significant sleep disturbances and daytime sleepiness.
6 is a common disease, responsible for daytime sleepiness.
7 excessive sleep, and its links to excessive sleepiness.
8 p deprivation-induced increase in subjective sleepiness.
9 ociated with reduced alertness and increased sleepiness.
10 iness scale, 1312 (28.5%) reported excessive sleepiness.
11 y significant decrease in subjective daytime sleepiness.
12 on reward sensitivity either directly or via sleepiness.
13 thalamic injury, with inactivity and daytime sleepiness.
14 imilar in terms of their impact on objective sleepiness.
15 mon in older adults, was not associated with sleepiness.
16 44) complaints of frequent excessive daytime sleepiness.
17 ven beverages per week) reduced the risk for sleepiness.
18 hase advances, respectively, without causing sleepiness.
19 commonly present in those with complaints of sleepiness.
20 ective reports of depressed mood and current sleepiness.
21 rtant consequences such as excessive daytime sleepiness.
22 ve useful in prediction of excessive daytime sleepiness.
23 ce sleep fragmentation and excessive daytime sleepiness.
24 effects may not be directly attributable to sleepiness.
25 ariation of obesity with snoring and daytime sleepiness.
26 e important outcome, the severity of daytime sleepiness.
27 healthy subjects, which are associated with sleepiness.
28 This effect was related to the level of sleepiness.
29 se (CAD), many of whom do not report daytime sleepiness.
30 Food consumption is thought to induce sleepiness.
31 he relationship between mild OSA and daytime sleepiness.
32 y, poor sleep quality, and excessive daytime sleepiness.
33 omycin on objective vigilance and subjective sleepiness.
34 ansient but substantial increases in daytime sleepiness.
35 so associated with reduced AHI and excessive sleepiness.
36 delayed sleep habits, and excessive daytime sleepiness.
37 ures include snoring, witnessed apnoeas, and sleepiness.
38 /hypocretin (OH) neurons causes pathological sleepiness [1-4], whereas OH hyperactivity is associated
39 nterval): 2.97 (2.65-3.34)), regular daytime sleepiness (2.66 (2.34-3.01)), and regular insomnia (2.3
40 nd 1.33; P < 0.001 for all domains), daytime sleepiness (-2.92; P < 0.001), mood state (-4.24; P = 0.
41 h risk for OSAS, 46.3% had excessive daytime sleepiness, 41.5% were positive for both the Bq and ESS,
43 annoyance, disturbs sleep and causes daytime sleepiness, affects patient outcomes and staff performan
44 ions, moving violations, aggressive driving, sleepiness, alcohol abuse, metabolic disorders, and mult
45 Acute melatonin suppression and subjective sleepiness also had a dose-dependent response to light e
47 in performance were independent of reported sleepiness and awareness of stimulus changes, arguing ag
48 sleep, is characterized by excessive daytime sleepiness and cataplexy, a loss of muscle tone triggere
50 Narcolepsy is characterized by excessive sleepiness and cataplexy, sudden episodes of muscle weak
55 a significant increase in daytime subjective sleepiness and changes in the EEG architecture of a subs
57 as been implicated in pathways that generate sleepiness and cognitive impairments, but existing mathe
60 vative strategies to minimize the effects of sleepiness and fatigue on patient care and resident safe
62 oor maintenance of wakefulness indicative of sleepiness and fragmented sleep and lacked any electroph
63 ocytes throughout the brain causes excessive sleepiness and fragmented wakefulness during the nocturn
67 etween increased levels of excessive daytime sleepiness and increased measures for adiposity traits (
68 es recurrent arousals from sleep, leading to sleepiness and increased risk of motor vehicle and occup
69 older people with OSA syndrome, CPAP reduces sleepiness and is marginally more cost effective over 12
70 not only because of the negative impacts of sleepiness and its root causes on health and social func
71 Because of the strong interactions between sleepiness and motivation, the role of sleepiness was al
72 nts receiving escitalopram had more frequent sleepiness and obstipation than did those in the other t
76 Narcolepsy with cataplexy, characterized by sleepiness and rapid onset into REM sleep, affects 1 in
77 iness Scale (ESS) was used to assess daytime sleepiness and standardized questionnaires assessed snor
78 to explore the relationship between daytime sleepiness and the risk of ischemic stroke and vascular
80 of characteristic history (snoring, daytime sleepiness) and physical examination (increased neck cir
81 ted with increases in fatigue (tiredness and sleepiness) and with deterioration in cognitive performa
82 e in obesity, 40% of the variance in daytime sleepiness, and 23% of the variability in self-reports o
83 ted sleep characteristics, excessive daytime sleepiness, and chronotype using the Pittsburgh Sleep Qu
86 triction, irregular sleep schedules, daytime sleepiness, and elevated risk for sleep disturbances.
87 cating patients about the risks of excessive sleepiness, and encouraging clinicians to become familia
90 ant interactions between eczema and fatigue, sleepiness, and insomnia as predictors of poorer overall
92 e, the visual analog scale score for daytime sleepiness, and sleep log-derived and actigraphy-derived
93 ep are not associated with excessive daytime sleepiness, and therefore appear unlikely to contribute
95 clinical features (i.e., significant daytime sleepiness, anxiety and depression symptoms, potential f
96 igue (aOR, 1.59; 95% CI, 1.16-2.19), daytime sleepiness (aOR, 1.81; 95% CI, 1.28-2.55), or insomnia (
98 ith the respiratory cycle predicted next-day sleepiness as measured by the multiple sleep latency tes
100 .6]; 13 trials, 543 participants), excessive sleepiness assessed by ESS score (WMD, -2.0 [95% CI, -2.
101 ine/after AAC; (3) hourly ammonia/subjective sleepiness assessment for 8 hours after AAC; (4) sleep E
103 oving wakefulness in patients with excessive sleepiness associated with narcolepsy, obstructive sleep
105 ystem disorders, including excessive daytime sleepiness, attention deficit hyperactivity disorder, Al
106 e associated with improvements in attention, sleepiness, behavior, and quality of life, and that chan
108 This study supports the notion that daytime sleepiness, but not nighttime sleeping duration, is one
111 Sleep Latency Test in all subjects, problem sleepiness by self-rating in 873, and subjective sleep p
112 ctive strategy for identifying biomarkers of sleepiness by using genetic and pharmacological tools th
113 disorder characterized by excessive daytime sleepiness, cataplexy, and other pathological manifestat
114 disorder characterized by excessive daytime sleepiness, cataplexy, hypnagonic hallucinations, sleep
115 criteria for diencephalic encephalitis with sleepiness, cataplexy, hypocretin deficiency, and centra
120 neurological underpinnings of alertness and sleepiness deepens, improved treatment methods are bound
122 nea syndrome can experience residual daytime sleepiness despite regular use of nasal continuous posit
124 rial stiffness), neurobehavioral (subjective sleepiness, driving simulator performance), and quality
126 rk sleep disorder chronically have excessive sleepiness during night work and insomnia when attemptin
127 ng chronotypes reported a faster increase in sleepiness during the day than evening chronotypes, whic
128 xploring the links between excessive daytime sleepiness (EDS) and vulnerability to infectious disease
129 tment of disorders such as excessive daytime sleepiness (EDS) as well as other sleep or cognitive dis
133 ng and between obesity and excessive daytime sleepiness (EDS), although for the most part the genetic
134 g risk, inquiring about additional causes of sleepiness, educating patients about the risks of excess
135 rcentage of patients with normalized daytime sleepiness (Epworth score < 10) was significantly higher
137 sleepiness, patients with excessive daytime sleepiness (Epworth Sleepiness Scale score >/=10) had a
139 pnea-hypopnea index >/=15/h) without daytime sleepiness (Epworth Sleepiness Scale score <10) were ran
140 (Pittsburgh Sleep Quality Index) and daytime sleepiness (Epworth Sleepiness Scale), and circadian mar
141 r 1 wk at home and sleep apnea in subjective sleepiness (Epworth Sleepiness Scale), objective sleepin
142 tual snorers, 18% reported excessive daytime sleepiness (ESS > or = 11), and 29% were obese (body mas
143 olepsy is characterized by excessive daytime sleepiness, fragmentation of nighttime sleep, and catapl
144 n/hypocretin signaling, resulting in chronic sleepiness, fragmented non-rapid eye movement sleep, and
146 rome occurs, which includes fever, anorexia, sleepiness, hyperalgesia and elevated corticosteroid sec
147 sleepier on the MSLT and reported increased sleepiness, hypnagogic hallucinations and cataplexy-like
150 ncrease in ammonia concentrations/subjective sleepiness in both patients and healthy volunteers; (ii)
154 elf-reported symptoms of snoring and daytime sleepiness in older men have a genetic basis that is lar
155 multiple risk factors for excessive daytime sleepiness in older subjects (mean age, 78 years; range
156 However, treatment of mild OSA may improve sleepiness in patients who are sleepy at baseline and im
157 produces an improvement in excessive daytime sleepiness in patients with Cheyne-Stokes breathing and
158 tment for the management of residual daytime sleepiness in patients with obstructive sleep apnea/hypo
168 ibe the effectiveness of countermeasures for sleepiness, including recent work-hour restrictions.
170 dical disorder that causes excessive daytime sleepiness, increasing the risk for drowsy driving two t
171 gether, our findings show that the excessive sleepiness incurred by recurrent arousals during sleep m
172 iated with atopy, fatigue, excessive daytime sleepiness, insomnia, and only 0 to 3 nights of sufficie
173 by neurologists, including excessive daytime sleepiness, insomnia, narcolepsy, rapid eye movement sle
175 h and social function, but because excessive sleepiness is generally remediable with appropriate trea
178 not affect rhythms of subjective hunger and sleepiness, master clock markers (plasma melatonin and c
181 Preliminary evidence suggests that daytime sleepiness may predate clinical diagnosis of Parkinson d
183 ference, -0.42 [0.09], P < .001) and daytime sleepiness (mean [SE] difference, -0.24 [0.09], P = .006
186 circadian effects were observed for reported sleepiness, mood, and reported effort; the effects on wo
188 ion, cardiovascular disease, stroke, daytime sleepiness, motor vehicle accidents, and diminished qual
189 males and WDR27 in males), excessive daytime sleepiness (near AR-OPHN1) and a composite sleep trait (
190 tle change in point estimates of effect, but sleepiness no longer had a statistically significant ass
192 osterior hypothalamus completely rescued the sleepiness of these mice, but their fragmented sleep was
194 rovements in attention deficits (P < 0.001); sleepiness on the Epworth Sleepiness Scale (P < 0.001);
197 (P = .009, I2 = 74%), and excessive daytime sleepiness (OR, 2.27; 95% CI, 1.54-3.35) (P < .001, I2 =
198 2.65; P=0.023), those with excessive daytime sleepiness (OR, 2.51; P=0.037), and those with >/=2 medi
199 (P = .003, I2 = 76%), and excessive daytime sleepiness (OR, 2.72; 95% CI, 1.32-5.61) (P = .007, I2 =
200 that eczema associated with fatigue, daytime sleepiness, or insomnia was associated with even higher
201 y and fatigue, depression, excessive daytime sleepiness, or rapid eye movement sleep behaviour disord
204 measured duration and fragmentation, daytime sleepiness, overall quality, self-reported duration) wer
206 iated with arousals predicted less objective sleepiness (p = 0.008); rates of leg movements without a
207 nts were associated with decreased objective sleepiness (p = 0.03) but explained less than 1% of the
208 ng history, pRBD was associated with greater sleepiness (p=0.001), depression (p=0.001) and cognitive
210 d with PD patients without excessive daytime sleepiness, patients with excessive daytime sleepiness (
212 circadian rhythms in core body temperature, sleepiness, power in the theta band of the wake EEG, sle
213 led clinical trials with the endpoints being sleepiness, quality of life, and 24-h ambulatory blood p
214 s not only patient-reported outcomes such as sleepiness, quality of life, and mood but also intermedi
215 tive sleepiness at 12 months, plus objective sleepiness, quality of life, mood, functionality, noctur
216 +/- 5, respectively), functional outcomes of sleepiness questionnaire, short-form 36 health survey me
217 battery consisting of cognitive subtests, a sleepiness rating scale, and a mood scale, to predict ne
218 piness (Epworth Sleepiness Scale), objective sleepiness (reduced sleep latency as determined by the M
219 onger to fall asleep and had reduced evening sleepiness, reduced melatonin secretion, later timing of
223 13], P = .01) and incident OSA with habitual sleepiness (RR, 1.18 [95% CI, 1.07-1.31], P = .02).
224 associated with new-onset OSA with habitual sleepiness (RR, 2.72 [95% CI, 1.26-5.89], P = .045).
226 rimary outcome was 6-month change in Epworth Sleepiness Scale (ESS) score, which ranges from 0 (no da
228 ty, area under the curve (AUC), AHI, Epworth Sleepiness Scale (ESS) scores, blood pressure, mortality
230 he Berlin questionnaire (Bq) and the Epworth sleepiness scale (ESS) were applied to determine the ris
231 Secondary outcomes included the Epworth Sleepiness Scale (ESS), the Sleep Apnea Symptoms Questio
233 h Sleep Quality Index (PSQI) and the Epworth Sleepiness Scale (ESS, which assesses daytime hypersomno
234 icits (P < 0.001); sleepiness on the Epworth Sleepiness Scale (P < 0.001); behavior (P < 0.001); and
236 the Pittsburgh Sleep Quality Index, Epworth Sleepiness Scale and Morningness-Eveningness Questionnai
237 ses in subjective somnolence (via Karolinska Sleepiness Scale and Visual Analogue Scale measures) and
238 correlation between the decrease in Epworth Sleepiness Scale at 3 months and adherence (r = 0.411; P
242 s with excessive daytime sleepiness (Epworth Sleepiness Scale score >/=10) had a significantly lower
243 th self-reported daytime sleepiness (Epworth Sleepiness Scale score >10) and an apnea-hypopnea index
244 >/=15/h) without daytime sleepiness (Epworth Sleepiness Scale score <10) were randomized to auto-titr
245 rovements in EDS, as assessed by the Epworth Sleepiness Scale score (mean [SD], 15.81 [3.10] at basel
246 sequent self-reported error with the Epworth Sleepiness Scale score (odds ratio [OR], 1.10 per unit i
247 utcome measure was the change in the Epworth Sleepiness Scale score comparing the bright LT with the
248 index of 20 h(-1) or greater and an Epworth Sleepiness Scale score of 10 or less (scores range from
249 th coexistent EDS, as assessed by an Epworth Sleepiness Scale score of 12 or greater, and without cog
250 of 57.1 (10.1) years and a mean (SD) Epworth Sleepiness Scale score of 9.8 (4.4), and 77.5% were post
252 reater mean changes from baseline in Epworth Sleepiness Scale scores at Weeks 1 and 4 (p < 0.001) and
253 s in the intervention group, with Karolinska sleepiness scale scores of 6.65 (95% CI, 6.35-6.97) vs 7
254 of the Northern Manhattan Study, the Epworth Sleepiness Scale was collected during the 2004 annual fo
255 ed by using a questionnaire with the Epworth Sleepiness Scale) were assessed before and immediately a
256 ality Index) and daytime sleepiness (Epworth Sleepiness Scale), and circadian markers of the melatoni
257 leep apnea in subjective sleepiness (Epworth Sleepiness Scale), objective sleepiness (reduced sleep l
258 Of the 4608 participants who completed the sleepiness scale, 1312 (28.5%) reported excessive sleepi
259 ypopnea index, 41 [35-53]; mean [SD] Epworth sleepiness scale, 9.3 [4.2]) were randomized to effectiv
260 luded the Epworth Sleepiness Scale, Stanford Sleepiness Scale, Functional Outcomes of Sleep Questionn
262 igit Span Test Forward and Backward, Epworth Sleepiness Scale, SteerClear, Digit Symbol, Controlled O
263 Secondary outcome measures were the Epworth Sleepiness Scale, the Functional Outcomes of Sleep Quest
268 , the respiratory disturbance index (RDI), a sleepiness score, the arousal index, and sleep-associate
269 h a specialist model did not result in worse sleepiness scores, suggesting that the 2 treatment modes
270 ously significant risk factors for excessive sleepiness: severe sleep-disordered breathing (apnea-hyp
273 y, poor sleep quality, and excessive daytime sleepiness, studied according to an a priori protocol.
275 tudy, subjective ratings of treatment value, sleepiness, symptoms, and well-being, and objective test
277 with 200 mg of modafinil reduced the extreme sleepiness that we observed in patients with shift-work
280 Active treatment reduced excessive daytime sleepiness; the mean Osler change was +7.9 minutes (SEM
281 Although OSA is a risk factor for excessive sleepiness, there is developing evidence that it is also
283 (ESS) score, which ranges from 0 (no daytime sleepiness) to 24 points (high level of daytime sleepine
284 hy might be unable, due to excessive daytime sleepiness, to accumulate the need/ability to produce re
289 ost part the genetic variance in snoring and sleepiness was nonoverlapping with the genetic variance
292 nt efficacy and satisfaction, and subjective sleepiness were also better with CPAP than with MRS (eff
294 t) and OSA concomitant with habitual daytime sleepiness were estimated using repeated-measures Poisso
298 ted with the increased alertness and reduced sleepiness when methylphenidate was administered after s
299 Modafinil significantly improved daytime sleepiness, with significantly greater mean changes from
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。